Skip to main content

Table 3 Ongoing or recently completed clinical trials involving molecules that target apoptosis

From: Apoptosis in cancer: from pathogenesis to treatment

Molecule name Sponsor Target Condition Clinical stage
ABT-263
(in combination with erlotinib or irinotecan)
Abbott Bcl-2 family of proteins Solid tumours Phase I
ABT-263
(in combination with docetaxel)
Abbott Bcl-2 family of proteins Solid tumours Phase I
ABT-263
(in combination with paclitaxel)
Abbott Bcl-2 family of proteins Chronic lymphocytic leukaemia Phase I
ABT-263 Genentech Bcl-2 family of proteins Chronic lymphocytic leukaemia Phase II
AT-101
(Gossypol)
Roswell Park Cancer Institute Bcl-2 family of proteins Lymphocytic leukaemia,
chronic B-cell leukaemia
Phase I
Phase II
AT-406 Ascenta Therapeutics IAPs Solid tumours,
lymphoma
Phase I
AT-406 Ascenta Therapeutics IAPs Acute myelogenous leukaemia Phase I
ENZ-3042 Therapeutic Advances in Childhood Leukaemia Consortium IAPs Acute, childhood and T cell lymphoblastic leukaemia Phase I
GX15-070MS
(Obotoclax)
Children's Oncology Group Bcl-2 family of proteins Leukaemia,
lymphoma
unspecified childhood solid tumour
Phase I
GX15-070MS
(Obotoclax)
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute Bcl-2 family of proteins Lymphoma Phase I
Phase II
HGS-1029 Human Genome Sciences IAPs Advanced solid tumours Phase I
HGS-1029 Human Genome Sciences IAPs Advanced solid tumours Phase I
LCL-161 Novartis Pharmaceuticals IAPs Solid tumours Phase I
RO5458640 Hoffmann-La Roche TNF-like weak inducer of apoptosis (TWEAK) ligand Advanced solid tumours Phase I